RVMD insider sale: Wei Lin disposes 2,160 shares under 10b5-1 plan

Rhea-AI Filing Summary

Wei Lin, Chief Medical Officer of Revolution Medicines, Inc. (ticker shown in filing as RVMD), reported a sale of 2,160 shares of Common Stock on 09/16/2025 at a price of $45.8249 per share. The filing states the sale was made under a Rule 10b5-1 instruction adopted on December 23, 2024 to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025. After the transaction, Wei Lin beneficially owned 88,339 shares, which the filing notes includes 58,850 restricted stock units. The form was signed by an attorney-in-fact on behalf of Wei Lin on 09/18/2025.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating the transaction was pre-planned and reduces appearance of opportunistic insider trading
• Substantial remaining ownership of 88,339 shares including 58,850 RSUs, showing continued alignment with shareholders

Negative

• Insider sold shares (2,160 shares), which some investors may view as a liquidity event despite being for tax withholding

Insights

Securities Analyst

TL;DR: Insider sale executed under a 10b5-1 plan to cover tax withholding; remaining holdings remain substantial and include RSUs.

The reported sale of 2,160 shares at $45.8249 appears to be a routine, pre-planned disposition under a Rule 10b5-1 instruction adopted December 23, 2024. Such plans are commonly used to satisfy tax obligations tied to equity vesting and reduce allegations of opportunistic trading. The filing discloses that Wei Lin continues to beneficially own 88,339 shares including 58,850 RSUs, indicating sustained equity exposure to the company’s performance rather than a full exit. This transaction by itself is informational and does not, based on the filing alone, indicate a change in corporate outlook or governance.

Corporate Governance Expert

TL;DR: Transaction governed by 10b5-1 plan reduces regulatory risk; disclosure is consistent and specific.

The Form 4 provides clear mechanics: a sale under a documented 10b5-1 plan to meet tax withholding from RSU vesting. The inclusion of the adoption date of the plan and the explanation that the sale satisfied withholding obligations enhances transparency. The signature by an attorney-in-fact is properly noted. From a governance perspective, this is a standard, compliant disclosure and does not raise immediate red flags in the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Wei Lin

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S(1)		2,160	D	$45.8249	88,339(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.

2. Includes 58,850 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Wei Lin	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Wei Lin (Revolution Medicines) report on Form 4?

The filing reports a sale of 2,160 shares of common stock on 09/16/2025 at $45.8249 per share executed under a Rule 10b5-1 plan.

Why were the shares sold according to the Form 4?

The sale was made to satisfy tax withholding obligations upon the vesting of restricted stock units pursuant to a 10b5-1 instruction adopted on December 23, 2024.

How many shares does Wei Lin beneficially own after the transaction?

After the reported transaction Wei Lin beneficially owned 88,339 shares, which the filing states includes 58,850 RSUs.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of Wei Lin by Jack Anders, as Attorney-in-fact on 09/18/2025.

Does the filing indicate any derivative transactions or option exercises?

No. The filing’s Table II (derivative securities) contains no reported transactions; only a non-derivative sale of common stock is disclosed.